Budget Impact Analysis of Bevacizumab Plus Chemotherapy Versus Bevacizumab and Anti-Egfr With Chemotherapy for First and Second Line Treatment of Metastatic Colorectal Cancer in Russian Federation
Abstract
Authors
R. Yagudina A. Kulikov I. Komarov